Drug Profile
SP 0202
Alternative Names: GBP-410; Next Gen PCV - Sanofi; Next-generation pneumococcal conjugate vaccine - Sanofi/SK Bioscience; Pneumococcal vaccine conjugate - Sanofi Pasteur/SK Bioscience; SP-0202; SP0202-IIb; SP0202-VI; SP0202-VIILatest Information Update: 13 Oct 2023
Price :
$50
*
At a glance
- Originator sanofi pasteur; SK Chemicals
- Developer Sanofi; Sanofi Pasteur; SK Bioscience; SK Chemicals
- Class Conjugate vaccines; Pneumococcal vaccines; Polysaccharides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Pneumococcal infections
Most Recent Events
- 10 Aug 2023 Sanofi completes a phase-II trial in Pneumococcal infections (In infants, Prevention) in USA, Canada, Puerto Rico and Honduras (IM) (NCT04398706)
- 29 Jun 2023 Sanofi intends to file regulatory application in 2027
- 29 Jun 2023 Adverse events data from a phase II trial (In infants) for the prevention of Pneumococcal infections released by SK bioscience and Sanofi